EA5162
|
ECOG-ACRIN
|
Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
EA5163
|
ECOG-ACRIN
|
INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA5181
|
ECOG-ACRIN
|
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA5182
|
ECOG-ACRIN
|
Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA5191
|
ECOG-ACRIN
|
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA5221
|
ECOG-ACRIN
|
A Randomized Phase III Trial of Chemo Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA6134
|
ECOG-ACRIN
|
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA6141
|
ECOG-ACRIN
|
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA6174
|
ECOG-ACRIN
|
STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab, a Phase III Trial
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA6183
|
ECOG-ACRIN
|
A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|